Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Pisick, EP; Garrett-Mayer, E; Halabi, S; Mangat, PK; Yang, ES-H; Dib, EG; Burgess, EF; Zakem, MH; Rohatgi, N; Bilen, MA; Warren, SL; Anderson, ST; Rygiel, AL; Schilsky, RL

Published Date

  • May 20, 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X